Happy Holidays from the HDSA Family
Posted on December 24, 2020
Despite the challenges of 2020, your support of HDSA this year has continued to remind all of us that in the fight against Huntington’s…
Read MorePublication from an HDSA Fellow
Posted on December 17, 2020
Congratulations to 2019 Berman-Topper Fellow Dr. Lauren Byrne, whose work was recently published in the Journal Science Translational Medicine. She tweeted this week about…
Read MoreThe Marker: HDSA’s Annual Research Report
Posted on December 10, 2020
Each year HDSA’s annual research report, The Marker, covers the past year in HD science and HDSA research activities. Check…
Read MoreHDSA Announces Four 2020 Human Biology Fellows
Posted on December 3, 2020
This week, HDSA announced the winners of the 2020 HD Human Biology Fellowship. HDSA’s largest research initiative, the Human Biology Project supports projects that focus…
Read MoreHappy Thanksgiving
Posted on November 26, 2020
Happy Thanksgiving and a big thank you to members of the HD community for your participation in research. Medicine moves…
Read MorePTC Therapeutics Initiates Phase 1 Clinical Trial
Posted on November 19, 2020
PTC Therapeutics is a company focused on developing genetic and small molecule therapies for rare and serious disorders. This week they issued…
Read MoreTriplet Therapeutics SHIELD-HD study fully recruited
Posted on November 12, 2020
Triplet Therapeutics is a Boston-based biotech company that is developing therapies for CAG repeat disorders like HD. Their focus is studying…
Read MoreHDBuzz: Clinical Research Updates from the HSG Conference
Posted on November 5, 2020
The Huntington Study Group hosted a virtual conference from October 29th – 31st, covering clinical trial updates, education, and training for HD…
Read MoreHSG 2020: HD in Focus
Posted on October 29, 2020
The Huntington Study Group is a clinical research network focused exclusively on Huntington disease. Each year they host a conference that provides education…
Read MoreNovartis Receives FDA Orphan Drug Designation to Study Potential HD Treatment
Posted on October 22, 2020
This week the pharmaceutical company Novartis announced that they had received special status from the FDA, known as Orphan Drug Designation,…
Read MoreuniQure Trial Proceeds; Voyager Receives Regulatory Feedback
Posted on October 15, 2020
This week uniQure shared a press release stating that another two patients have entered their HD clinical trial. The drug, AMT-130, is an experimental gene therapy that…
Read MoreHDBuzz Covers Virtual EHDN Conference
Posted on October 8, 2020
The European Huntington’s Disease Network hosts a yearly Plenary meeting to discuss the latest in HD science and clinical trials,…
Read MoreHD Trialfinder: Study Updates
Posted on October 1, 2020
HDSA’s HD Trialfinder is an easy-to-use website that lists currently recruiting HD clinical trials in the United States and Canada. By answering some basic questions about…
Read MoreSIGNAL study of pepinemab does not meet key goals for HD patients
Posted on September 24, 2020
The SIGNAL study was carried out by a company called Vaccinex to test whether their drug, pepinemab, could combat brain inflammation and ease symptoms…
Read MoreHighlights from the EHDN Virtual Congress
Posted on September 17, 2020
This week the 2020 European Huntington’s Disease Network (EHDN) hosted a virtual plenary meeting to discuss the latest in HD research…
Read MoreYou Asked the Scientists!
Posted on September 10, 2020
The recording from the latest HDSA Research Webinar, Ask the Scientist Anything, is now available on HDSA’s YouTube channel. Dr….
Read MoreResearch Webinar: Ask the Scientist…Anything!
Posted on September 3, 2020
This coming Tuesday, September 8th, at 12 PM Eastern, Dr. Ed Wild and Dr. Jeff Carroll, creators of HDBuzz, as well as HDBuzz writers Dr….
Read MoreHDBuzz on Somatic Instability
Posted on August 27, 2020
The cause of Huntington’s disease is an extra-long stretch of CAG repeats in the DNA, in a single gene called huntingtin. In…
Read MoreResearch Spotlight: Telemedicine for Huntington’s Disease
Posted on August 20, 2020
Participants diagnosed with HD, ages 18-70, in the Chicago area, are needed for an HDSA-funded study on Telemedicine at Northwestern…
Read MoreHDBuzz: CRISPR Requires Caution
Posted on August 13, 2020
CRISPR is a gene editing technique that has been touted for its potential to treat HD someday in the future. However,…
Read More